These findings support that these compounds could improve hemostatic disorder and reduce the risk of diabetes associated atherogenesis and thrombosis via decreasing triglyceride level in circulation and cardiac tissue as well as enhancing activity of fibrinolytic factors such as AT-III and protein C. On the other hand, fibrinogen is a precursor in fibrin formation and a cofactor in platelet aggregation; PAI-1 is the primary physiologic inhibitor of fibrinolysis [22]. The gene discussed is SERPINE1; the disease is diabetes mellitus.